Billion Dollar Trio: Sana,Beam,Tessera Financings Raise $1.1B

U.S. Securities and Exchange Commission. Sana Biotechnology, Form 424B4, Form of prospectus disclosing information facts events covered in both forms 424B1 424B3. Filed February 5, 2021. https://ir.sana.com/static-files/9db9ce76-6382-47b7-a445-ebf3c46705d9 (last accessed February 7, 2021 ).

Beam Therapeutics . Beam Therapeutics Inc . announces $260 million common stock investment from multiple investors. January 19, 2021. https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-inc-announces-260-million-common-stock (last accessed February 7, 2021 ).

Koblan LW , Erdos MR , Wilson C , et al. In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice. Nature, 2021; 589:608–614.

Tessera Therapeutics . Tessera therapeutics attracts over $230M in series B financing to advance ‘gene writing’—a new category in genetic medicine. January 12, 2021. https://www.businesswire.com/news/home/20210112005242/en/Tessera-Therapeutics-Attracts-Over-230M-in-Series-B-Financing-to-Advance-%E2%80%98Gene-Writing%E2%80%99-%E2%80%93-A-New-Category-in-Genetic-Medicine (last accessed February 7, 2021 ).

Editas Medicine . Editas Medicine announces appointment of James C. Mullen as Chief Executive Officer. February 8, 2021. https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-appointment-james-c-mullen-chief (last accessed February 7, 2021 ).

Philippidis A. , Sangamo CEO Ponders Pipeline, reflects on phase III ‘Proud Moment’. Genetic Engineering & Biotechnology News, February 1, 2021. https://www.genengnews.com/gen-edge/sangamo-ceo-ponders-pipeline-reflects-on-phase-iii-proud-moment (last accessed February 10, 2021 ).

Frangoul H , Altshuler D , Cappellini D , et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med, 2021; 384:252–260.

Stein R . 1st patients to get CRISPR gene-editing treatment continue to thrive. National Public Radio, December 15, 2020. https://www.npr.org/sections/health-shots/2020/12/15/944184405/1st-patients-to-get-crispr-gene-editing-treatment-continue-to-thrive (last accessed February 11, 2021 ).

Wilkinson AC , Dever DP , Baik R , et al. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat Commun, 2021; 12:686.